EN DE
Watch Bait Bakfar Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bait Bakfar Ltd (BKFR) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Bait Bakfar Ltd stock ILS 9.75, price ILS 20.24, that is 51.8% below the price, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare Il · ISIN IL0011836561

BB Bait Bakfar Ltd logo Broad data Nov 2, 2026

Bait Bakfar Ltd

BKFR · TA
Solid, but very expensive

Our calculation puts a fair price 52% below what the stock costs today.

Healthy Growth (revenue 5y +5.4 %/yr in ILS)
Highly profitable · 139.8% net margin (TTM)
Low debt
Generates free cash flow
Ranks above peers (10/14)
Broad data
Costs just 8.8 times its yearly profit.
Quality 59/100
Moderate moat 60/100 · thin data
Fair value 9.75 ILS · Strongly overvalued
Watch Bait Bakfar Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

20.24 ILS 7.38 ILS Fair Value 9.75 ILS Jan 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.

How to read this chart

58‑month range 7.38 ILS – 20.24 ILS · fair‑value band 7.00 ILS – 12.54 ILS · the 20.24 ILS price screens above the 9.75 ILS fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.

Follow Bait Bakfar in your weekly email

Every Wednesday you see whether Bait Bakfar is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bait Bakfar Ltd manages and operates assisted living networks in Israel. The company offers health, welfare, and leisure services for the elderly population. Bait Bakfar Ltd was founded in 1988 is based in Kfar Saba, Israel.

Stock analysis

Bait Bakfar Ltd (BKFR) currently trades at 20.24 ILS, while our model-based Fair Value estimate is 9.75 ILS, 52% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 28.47 ILS per share, and 6 of the 26 models we run sit above the 20.24 ILS price.

Bear case: the Dividend Discount group reads lowest at 5.12 ILS, and 20 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: 7.00 ILS (bear) to 12.54 ILS (bull), the price of 20.24 ILS sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Bait Bakfar Ltd reported revenue of 110M ILS in FY2025 versus 85.4M ILS in FY2021, a compound +6.4%/yr. Reported net income was 107M ILS in FY2025, compounding +18.1%/yr from FY2021.

Key figures

Market cap 1.4B ILS Small · P/E ratio 8.8 · P/S ratio 12.2 · EPS (TTM) 2.29 ILS · Dividend yield 2.1% · Net margin 140% · Return on equity 13.3% · Return on assets (EBIT) 6.9% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 56% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −52%, BKFR screens richer than that median.

Fair Value models

Bear 7.00 ILS Fair Value 9.75 ILS Bull 12.54 ILS
Price 20.24 ILS · Downside -51.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.60 ILS per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 6.98 ILS 10.08 ILS 13.98 ILS 81
Growth DCF 7.05 ILS 9.79 ILS 13.05 ILS 79
Owner Earnings 17.88 ILS 25.10 ILS 34.16 ILS 77
All 26 models by family
DCF Models
FCF DCF 6.98 ILS 10.08 ILS 13.98 ILS 81
Owner Earnings 17.88 ILS 25.10 ILS 34.16 ILS 77
5Y Revenue Exit 4.01 ILS 5.84 ILS 8.02 ILS 73
5Y EBITDA Exit 5.70 ILS 8.93 ILS 12.54 ILS 75
5Y P/E Exit 15.01 ILS 25.91 ILS 37.12 ILS 70
10Y Revenue Exit 5.14 ILS 6.95 ILS 9.11 ILS 68
10Y EBITDA Exit 6.17 ILS 8.83 ILS 12.11 ILS 69
10Y P/E Exit 11.41 ILS 19.20 ILS 28.45 ILS 63
Earnings-Based
Graham-Dodd 10.38 ILS 28.65 ILS 37.62 ILS 65
Lynch FV 5.72 ILS 8.17 ILS 10.61 ILS 61
PEG = 1.0 5.72 ILS 8.17 ILS 10.61 ILS 57
EPV 1.23 ILS 1.55 ILS 1.82 ILS 74
Dividend Discount
Gordon GGM 3.19 ILS 5.58 ILS 7.49 ILS 68
DDM Multi-Stage 3.19 ILS 4.66 ILS 5.97 ILS 67
Multiples
P/E Multiple 25.18 ILS 33.58 ILS 41.97 ILS 63
P/S Multiple 4.11 ILS 5.49 ILS 6.86 ILS 58
P/B Multiple 59.72 ILS 79.63 ILS 99.53 ILS 55
EV/EBIT 7.00 ILS 9.75 ILS 12.50 ILS 66
EV/EBITDA 5.61 ILS 7.90 ILS 10.18 ILS 67
EV/Revenue 2.05 ILS 3.46 ILS 4.87 ILS 52
Asset-Based
NCAV (Graham) 8.85 ILS 11.86 ILS 17.69 ILS 54
Growth DCF
Growth DCF 7.05 ILS 9.79 ILS 13.05 ILS 79
Rev-Margin DCF 4.01 ILS 5.76 ILS 7.64 ILS 73
Economic Profit
Residual Income 14.00 ILS 14.68 ILS 16.19 ILS 76
ROIC Compounder 1.23 ILS 1.55 ILS 1.82 ILS 72
Growth Earnings
Growth-Adj P/E 19.93 ILS 28.47 ILS 37.01 ILS 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 59/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 37
How much profit the company makes from its sales and capital
Quality Growth 31
Are margins and returns getting better?
Cashflow 76
Do the profits arrive as real cash?
Financial strength 57
Debt, balance sheet and risk of trouble
Investment 63
Does it invest with discipline instead of growing at any price?
Low Volatility 62
How calm the share price moves, does not count
Price momentum 64
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 87
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 80/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+16.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.1%
Dividend (yield on the price)2.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.51% → 41%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about +12.2% a year for the price.

BKFR screens overvalued: fair value 52% below the price. Compare with HCA Healthcare, Inc →

Compare Bait Bakfar Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks

Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside −51.8% · Bottom 25%
Profitability
Return on equity (12 months) 13.3% · Above median
Return on assets 4.8% · Above median
Net margin (12 months) 139.8% · Top 25%
Operating margin (12 months) 41.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 14.1% · Above median
Dividend yield (12 months) 2.1% · Above median
Balance sheet
Debt / equity 0.08× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 8.8× · Cheapest 25%
P/B 1.14× · Cheaper than median
P/S (12 months) 12.23× · Priciest 25%
Price / free cash flow (fiscal year) 22.3× · Pricier than median
EV/EBITDA 31.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)71 · sector 31
PAST (return on equity)53 · sector 32
HEALTH (low debt)96 · sector 90
DIVIDEND (yield)42 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $23.40 $46.55 +99% vs BKFR
Aier Eye Hospital Group 300015 ¥9.01 ¥10.88 +21% vs BKFR
DaVita Inc DVA $191.35 $218.90 +14% vs BKFR
HCA Healthcare, Inc HCA $494.99 $547.34 +11% vs BKFR
Tenet Healthcare Corporation THC $283.33 $279.20 −1% vs BKFR
Encompass Health Corporation EHC $137.54 $94.81 −31% vs BKFR
IHH Healthcare Berhad 5225 7.70 MYR 5.23 MYR −32% vs BKFR
Fresenius SE FRE €52.48 €34.77 −34% vs BKFR
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,446 ₹5,234 −38% vs BKFR
Dr. Sulaiman Al Habib Medical Services Group 4013 215.00 SAR 109.45 SAR −49% vs BKFR

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bait Bakfar Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bait Bakfar Ltd Fair Value". https://www.fairvalue-calculator.com/stock/BKFR

Frequently asked questions

Is Bait Bakfar Ltd (BKFR) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of 9.75 ILS versus a price of 20.24 ILS, about 52% lower (overvalued).
What is the fair value of BKFR?
Our model-based fair value for Bait Bakfar Ltd is 9.75 ILS (as of Nov 2, 2026), built from audited fundamentals. The current price: 20.24 ILS.
What is the quality score of BKFR?
Bait Bakfar Ltd has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bait Bakfar Ltd (BKFR)?
Our model-based price target is the fair value of 9.75 ILS (as of Nov 2, 2026) from 26 valuation models. Cautious scenario 7.00 ILS, optimistic scenario 12.54 ILS. It is a calculation from audited fundamentals, not an analyst target.
What is the Bait Bakfar Ltd stock forecast for 2026?
Our models put fair value at 9.75 ILS, about 52% lower versus a price of 20.24 ILS (overvalued). Cautious scenario 7.00 ILS, optimistic scenario 12.54 ILS. The calculation is refreshed regularly with new filings.
What is the revenue of Bait Bakfar Ltd (BKFR)?
Bait Bakfar Ltd reported trailing-twelve-month revenue of about 116M ILS (latest available figure, as of Nov 2, 2026).
Does Bait Bakfar Ltd pay a dividend?
Bait Bakfar Ltd currently shows a dividend yield of 2.12% relative to its recent price (as of Nov 2, 2026).
How much is the dividend of Bait Bakfar Ltd (BKFR) and when is the ex-dividend date?
Bait Bakfar Ltd pays a dividend of 0.43 ILS per share a year, a dividend yield of 2.1%. The last ex-dividend date was Apr 16, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 18.8% of earnings. Free cash flow covers the dividend 2.11 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Bait Bakfar Ltd (BKFR)?
For today's price to be fair in a discounted-cash-flow model, Bait Bakfar Ltd would have to grow free cash flow by +14.6 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.4 % per year. As of Nov 2, 2026.
What discount rate (WACC) does the fair value of BKFR use?
Our models discount Bait Bakfar Ltd at 11.6 %: a base by market capitalisation (small), damped by beta 0.24, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bait Bakfar Ltd that is +14.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Bait Bakfar Ltd (BKFR) delivered so far?
Over the past 5 years revenue at Bait Bakfar Ltd grew +5.4 % a year. The price currently implies free-cash-flow growth of +14.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bait Bakfar Ltd (BKFR) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Bait Bakfar Ltd (+14.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bait Bakfar Ltd (BKFR)?
The free-cash-flow yield on the price is 4.49 %: that much free cash flow Bait Bakfar Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bait Bakfar Ltd (BKFR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bait Bakfar Ltd it is 9.75 ILS per share (as of Nov 2, 2026), against a price of 20.24 ILS. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Bait Bakfar Ltd stock overvalued or undervalued in 2026?
As of Nov 2, 2026, BKFR trades above its calculated fair value: price 20.24 ILS, fair value 9.75 ILS, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BKFR?
No. The price is what the market pays today (20.24 ILS); the fair value is what the company's own numbers justify (9.75 ILS). For Bait Bakfar Ltd the two are 10.49 ILS per share apart. That gap is exactly why we show both numbers side by side.
How much is Bait Bakfar Ltd worth?
The market values Bait Bakfar Ltd at about 1.4B ILS (market capitalisation, as of Nov 2, 2026). Per share that is 20.24 ILS; our models calculate a fair value of 9.75 ILS per share.
What do the bullish and bearish scenarios say about BKFR?
Our models span a range for Bait Bakfar Ltd: cautious scenario 7.00 ILS, base 9.75 ILS, optimistic 12.54 ILS per share (as of Nov 2, 2026, price 20.24 ILS). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BKFR?
Bait Bakfar Ltd trades at a price-to-earnings ratio of 8.8 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 9.75 ILS is built from several models across several years. Other multiples: P/B 1.1, P/S 12.2, EV/EBITDA 31.0.
How solid is the balance sheet of Bait Bakfar Ltd (BKFR)?
Balance-sheet figures for Bait Bakfar Ltd (as of Nov 2, 2026): return on equity 13.3%, debt of 0.08 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is BKFR from its 52-week high?
Bait Bakfar Ltd trades at 20.24 ILS, at its 52-week high of 20.24 ILS and 56% above the low of 12.93 ILS (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 9.75 ILS is for.
Which stocks are comparable to Bait Bakfar Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bait Bakfar Ltd stock attractive at the current price?
The data as of Nov 2, 2026: price 20.24 ILS, calculated fair value 9.75 ILS (−52%), Quality Score 59/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BKFR calculated?
We run Bait Bakfar Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 9.75 ILS builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Bait Bakfar Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bait Bakfar Ltd (BKFR)?
The closing price on Nov 6, 2026 was 20.24 ILS. Our model-based fair value is 9.75 ILS, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bait Bakfar Ltd right now?
The price sits above even our optimistic bull case (12.54 ILS). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Bait Bakfar Ltd

How large is the market capitalisation of Bait Bakfar Ltd (BKFR)?
The market capitalisation of Bait Bakfar Ltd is 1.4B ILS. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bait Bakfar Ltd (BKFR)?
The price-to-sales ratio of Bait Bakfar Ltd is 12.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bait Bakfar Ltd (BKFR)?
Earnings per share at Bait Bakfar Ltd are 2.29 ILS (price ÷ EPS = P/E 8.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bait Bakfar Ltd (BKFR)?
The dividend yield of Bait Bakfar Ltd is 2.1% (payout 18.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bait Bakfar Ltd (BKFR)?
The net margin of Bait Bakfar Ltd is 140% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bait Bakfar Ltd (BKFR)?
The return on equity (ROE) of Bait Bakfar Ltd is 13.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bait Bakfar Ltd (BKFR)?
On an EBIT basis the return on assets of Bait Bakfar Ltd is 6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bait Bakfar Ltd (BKFR)?
The operating margin of Bait Bakfar Ltd is 41.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bait Bakfar Ltd (BKFR)?
Revenue at Bait Bakfar Ltd is growing +14.1% versus a year earlier (3y avg +5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bait Bakfar Ltd (BKFR)?
Earnings per share at Bait Bakfar Ltd are growing +273% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bait Bakfar Ltd (BKFR) carry?
The net debt of Bait Bakfar Ltd is 86.8M ILS (fiscal year 2025, ≈ 1.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Bait Bakfar Ltd in the live analysis

One click puts Bait Bakfar Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.